


Claims:

1. A compound according to Formula I:



5

and pharmaceutically and/or veterinarily acceptable derivatives thereof, wherein:

R¹ is H;

- 10 R² is aryl, het, C₃₋₈cycloalkyl, C₁₋₆alkyl, (CH₂)₂aryl or R⁴, wherein each of the cycloalkyl, aryl, het and R⁴ groups is optionally substituted by at least one substituent independently selected from C₁₋₆alkyl, C₁₋₆alkoxy, OH, halo, CF₃, OCF₃, OCHF₂, O(CH₂)_yCF₃, CN, CONH₂, CON(H)C₁₋₆alkyl, CON(C₁₋₆alkyl)₂, hydroxy-C₁₋₆alkyl, C₁₋₄alkoxy-C₁₋₆alkyl, C₁₋₄alkoxy-C₁₋₄alkoxy, SCF₃, C₁₋₆alkylSO₂, C₁₋₄alkyl-S-C₁₋₄alkyl, C₁₋₄alkyl-S-,
- 15 C₁₋₄alkylNR¹⁰R¹¹ and NR¹⁰R¹¹;
or R¹ and R², together with the carbon atom to which they are bound, form a 5- or 6-membered carbocyclic ring or a 5- or 6-membered heterocyclic ring containing at least one N, O or S heteroatom;

- 20 where R¹ and R² are different, * represents a chiral centre;

- R³ is aryl, het or R⁴, each optionally substituted by at least one substituent independently selected from C₁₋₆alkyl, C₁₋₆alkoxy, het, OH, halo, CF₃, OCF₃, OCHF₂, O(CH₂)_yCF₃, CN, CONH₂, CON(H)C₁₋₆alkyl, CON(C₁₋₆alkyl)₂, hydroxy-C₁₋₆alkyl, C₁₋₄alkoxy-C₁₋₆alkyl, C₁₋₄alkoxy-C₁₋₄alkoxy, SCF₃, C₁₋₆alkylSO₂, C₁₋₄alkyl-S-C₁₋₄alkyl, C₁₋₄alkyl-S-, C₁₋₄alkylNR¹⁰R¹¹ and NR¹⁰R¹¹;
- 25

R⁴ is a phenyl group fused to a 5- or 6-membered carbocyclic group, or a phenyl group fused to a 5- or 6-membered heterocyclic group containing at least one N, O or S heteroatom;

63

R⁵ is H or C₁₋₆alkyl;

R¹⁰ and R¹¹ are the same or different and are independently H or C₁₋₄alkyl;

A is a C₁₋₃alkylene chain which is optionally substituted by OH, C₁₋₄alkyl or C₁₋₄alkoxy;

5 x is an integer from 1 to 3;

y is 1 or 2;

z is an integer from 1 to 3;

aryl is phenyl, naphthyl, anthracyl or phenanthryl; and

het is an aromatic or non-aromatic 4-, 5- or 6-membered heterocycle

10 which contains at least one N, O or S heteroatom, optionally fused to a 5- or 6-membered carbocyclic group or a second 4-, 5- or 6-membered heterocycle which contains at least one N, O or S heteroatom, provided that when R¹ is H, R² is phenyl, A is CH₂ and x is 1, R³ is not 3-hydroxyphenyl or 3-(C₁₋₄alkoxy)phenyl.

15

2. A compound according to Claim 1, wherein R¹ is H.

3. A compound according to Claim 1 or Claim 2, wherein R² is aryl, het or C₃₋₈cycloalkyl, each optionally substituted by at least one substituent

20 independently selected from C₁₋₆alkyl, C₁₋₆alkoxy, OH, halo, CF₃, OCF₃, OCHF₂, O(CH₂)_yCF₃, CN, CONH₂, CON(H)C₁₋₆alkyl, CON(C₁₋₆alkyl)₂, hydroxy-C₁₋₆alkyl, C₁₋₄alkoxy-C₁₋₆alkyl, C₁₋₄alkoxy-C₁₋₄alkoxy, SCF₃, C₁₋₆alkylSO₂ and C₁₋₄alkyl-S-C₁₋₄alkyl.

25 4. A compound according to Claim 3, wherein R² is aryl optionally substituted by at least one substituent independently selected from C₁₋₆alkyl, C₁₋₆alkoxy, OH, halo, CF₃, OCF₃, OCHF₂, O(CH₂)_yCF₃, CN, CONH₂, CON(H)C₁₋₆alkyl, CON(C₁₋₆alkyl)₂, hydroxy-C₁₋₆alkyl, C₁₋₄alkoxy-C₁₋₆alkyl, C₁₋₄alkoxy-C₁₋₄alkoxy, SCF₃, C₁₋₆alkylSO₂ and C₁₋₄alkyl-S-C₁₋₄alkyl.

30

5. A compound according to Claim 4, wherein R² is phenyl optionally substituted by at least one substituent independently selected from C₁₋₆alkyl, C₁₋₆alkoxy, OH, halo, CF₃, OCF₃, OCHF₂, O(CH₂)_yCF₃, CN, CONH₂,

64

CON(H)C₁₋₆alkyl, CON(C₁₋₆alkyl)₂, hydroxy-C₁₋₆alkyl, C₁₋₄alkoxy-C₁₋₆alkyl, C₁₋₄alkoxy-C₁₋₄alkoxy, SCF₃, C₁₋₆alkylSO₂ and C₁₋₄alkyl-S-C₁₋₄alkyl.

6. A compound according to any preceding claim, wherein R³ is aryl or
5 R⁴, each optionally substituted by at least one substituent independently
selected from C₁₋₆alkyl, C₁₋₆alkoxy, OH, halo, CF₃, OCF₃, OCHF₂,
O(CH₂)_yCF₃, CN, CONH₂, CON(H)C₁₋₆alkyl, CON(C₁₋₆alkyl)₂, hydroxy-C₁₋₆
alkyl, C₁₋₄alkoxy-C₁₋₆alkyl, C₁₋₄alkoxy-C₁₋₄alkoxy, SCF₃, C₁₋₆alkylSO₂ and
C₁₋₄alkyl-S-C₁₋₄alkyl.
- 10 7. A compound according to Claim 6, wherein R³ is phenyl optionally
substituted by at least one substituent independently selected from C₁₋₆
alkyl, C₁₋₆alkoxy, OH, halo, CF₃, OCF₃, OCHF₂, O(CH₂)_yCF₃, CN, CONH₂,
CON(H)C₁₋₆alkyl, CON(C₁₋₆alkyl)₂, hydroxy-C₁₋₆alkyl, C₁₋₄alkoxy-C₁₋₆alkyl,
15 C₁₋₄alkoxy-C₁₋₄alkoxy, SCF₃, C₁₋₆alkylSO₂ and C₁₋₄alkyl-S-C₁₋₄alkyl.
8. A compound according to any preceding claim, wherein R⁵ is H or
C₁₋₆alkyl.
- 20 9. A compound according to any preceding claim, wherein A is a
methylene (i.e. -CH₂-) group optionally substituted by OH.
10. A compound according to any preceding claim, wherein x is 1.
- 25 11. A compound according to Claim 1 which is (+) or (-)-1-[2-(2-
Ethoxyphenyl)-1-phenylethyl]piperazine.
12. A pharmaceutical composition comprising a compound as claimed
in any one of Claims 1 to 11 and a pharmaceutically acceptable adjuvant,
30 diluent or carrier.
13. A compound according to any one of Claims 1-11 for use as a
medicament.


14. Use of a compound according to any one of Claims 1-11 in the manufacture of a medicament for the treatment of a disorder in which the regulation of monoamine transporter function in mammals is implicated.
- 5 15. Use of a compound according to any one of Claims 1-11 in the manufacture of a medicament for the treatment of a disorder in which the regulation of serotonin or noradrenaline in mammals is implicated.
- 10 16. Use according to Claim 15, wherein the regulation of serotonin and noradrenaline is implicated.
- 15 17. Use of a compound according to any one of Claims 1-11 in the manufacture of a medicament for the treatment of urinary disorders, depression, pain, premature ejaculation, ADHD or fibromyalgia in mammals.
18. Use of a compound according to Claim 17, for the treatment of urinary incontinence, such as GSI or USI, in mammals.
- 20 19. A method of treatment of a disorder in which the regulation of monoamine transporter function is implicated which comprises administering a therapeutically effective amount of a compound according to any one of Claims 1-11 to a patient in need of such treatment.
- 25 20. A method of treatment of a disorder in which the regulation of serotonin or noradrenaline is implicated which comprises administering a therapeutically effective amount of a compound according to any one of Claims 1-11 to a patient in need of such treatment.
- 30 21. A method according to Claim 20, wherein the regulation of serotonin and noradrenaline is implicated.
22. A method of treatment of urinary disorders, depression, pain, premature ejaculation, ADHD or fibromyalgia, which comprises

66

administering a therapeutically effective amount of a compound according to any one of Claims 1-11 to a patient in need of such treatment.

23. A method according to Claim 22, wherein the urinary disorder is
5 urinary incontinence, such as GSI or USI.

24. A process for preparing a compound according to any one of Claims 1-11 comprising reacting a compound of Formula III




(III)

10

wherein R₂ and x are as defined in any of Claims 1 to 11 and PG is a protecting group;

with a compound of Formula IV



(IV)

15 wherein R₃ and A are as defined in any of Claims 1 to 11, M is a metal selected from Zn and Mg and Hal is a halogen atom selected from chlorine, bromine and iodine;
and deprotecting the resultant compound.

20